FDA Approves Pfizer's Tukysa Combination for Breast Cancer Maintenance

Key Facts

The US FDA approved Pfizer's Tukysa combination regimen for frontline maintenance treatment of breast cancer. Zacks Investment Research reported that this approval expands the drug's application to include earlier stages of the treatment cycle, moving it up from its previous second-line setting.

Pfizer (PFE) closed at $28 on October 7, 2026, with the stock trading between a day low of $27.55 and a high of $28.17 during that session. The regulatory expansion is intended to increase the potential patient pool and support long-term revenue growth for the company's oncology portfolio.